2 active not recruiting, 2 recruiting, 1 terminated, 1 withdrawn. 6 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Active not recruiting 2, Recruiting 2, Terminated 1, Withdrawn 1 |
| Phase 1 | 3 | Active not recruiting 1, Recruiting 1, Terminated 1 |
Follow Unresectable Triple-Negative Breast Carcinoma: new trials by email Literature Review of Unresectable Triple-Negative Breast Carcinoma trials Research Report on Unresectable Triple-Negative Breast Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer Alpha-type-1 Polarized Dendritic Cells, Biopsy, Computed Tomography - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2025-02-01 | 2025-01-29 | |
| Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer Biopsy, Biospecimen Collection, Computed Tomography - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 2 | Recruiting | Emory University | 37 | 2024-09-01 | 2026-06-04 |
| Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer Biopsy, Biospecimen Collection, Celecoxib - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma | Phase 1 / Phase 2 | Terminated | Roswell Park Cancer Institute | 5 | 2024-02-16 | 2026-08-31 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 138 | 2022-03-31 | 2026-08-20 |
| Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 24 | 2021-03-01 | 2026-07-31 |
| A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors 18F-Fluoromisonidazole, Cediranib Maleate, Laboratory Biomarker Analysis - Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 122 | 2016-08-31 | 2026-09-25 |
Triple Negative Breast Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (2) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Lobular (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Carcinosarcoma (1) · Endometrial Neoplasms (1) · Lung Neoplasms (1) · Melanoma (1) · Neoplasm Metastasis (1) · Small Cell Lung Carcinoma (1) · Squamous Cell Carcinoma of Head and Neck (1)
Breast Diseases (6) · Neoplasms (6) · Neoplasms by Site (6) · Skin Diseases (6) · Skin and Connective Tissue Diseases (6) · Breast Neoplasms (5) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Lung Diseases (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Thoracic Neoplasms (2) · Adenocarcinoma (1) · Carcinoma (1) · Carcinoma, Neuroendocrine (1)
Biopsy (5) · Magnetic Resonance Spectroscopy (4) · Specimen Handling (4) · pembrolizumab (4) · Celecoxib (1) · Colony-Stimulating Factors (1) · Cyclophosphamide (1) · Immunoglobulin G (1) · Interferon alpha-2 (1) · Leukapheresis (1) · Propranolol (1) · X-Rays (1) · cediranib (1) · copanlisib (1) · eribulin (1)
National Cancer Institute (NCI) (2) · Roswell Park Cancer Institute (2) · Emory University (1) · Mayo Clinic (1)
United States (6) · Canada (1)
Ellis Levine, MD (1) · Joseph W Kim (1) · Nusayba Bagegni (1) · Shipra Gandhi (1) · Shipra Gandhi, MD, MS (1) · Yanyan Lou, MD, PhD (1)
UM1CA186689 (2), K08CA279766 (1), P01CA234212 (1), UM1CA186644 (1), UM1CA186704 (1)